herein are for illustrative
purposes only and are based on management's current views and assumptions.
Such projections, forecast and estimates involve known and unknown risks
and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk
Factors) of the Document de Base available on ExonHit Therapeutics' website
), that may cause actual results, performance or events to
differ materially from those anticipated in the summary information.
In addition, ExonHit Therapeutics, its shareholders, and its
affiliates, directors, officers, advisors and employees have not verified
the accuracy of, and make no representations or warranties in relation to,
statistical data or predictions contained in this press release that were
taken or derived from third party sources or industry publications, and
such statistical data and predictions are used in this press release for
information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French language
version shall prevail.
EXONHIT THERAPEUTICS S.A.
CONSOLIDATED BALANCE SHEET
(in thousands of euros)
ASSETS 31, 2006 31, 2007
Intangible assets, net 577 81
Property and equipment, net 1,677 1,929
Other long term assets 1,387 1,664
Total long term assets 3,641 3,674
Accounts and grants receivable 1,879 1,151
Other short term assets 3,092 1,422
Cash and cash equivalents 23,972 31,342
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved
. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials2
. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood3
. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease4
. ExonHit and bioMerieux Amend Their Strategic Partnership5
. ExonHit Builds A New Organisation6
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA7
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review8
. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation9
. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway10
. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 200711
. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer